Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Net Cash Flow (2017 - 2020)

Monopar Therapeutics (MNPR) has disclosed Net Cash Flow for 4 consecutive years, with -$1.2 million as the latest value for Q4 2020.

  • Quarterly Net Cash Flow fell 114.31% to -$1.2 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2020, down 44.39% year-over-year, with the annual reading at $15.9 million for FY2025, 58.7% down from the prior year.
  • Net Cash Flow hit -$1.2 million in Q4 2020 for Monopar Therapeutics, down from $5.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $8.7 million in Q4 2019 to a low of -$1.2 million in Q4 2020.
  • Historically, Net Cash Flow has averaged $866983.8 across 4 years, with a median of -$622037.5 in 2019.
  • Biggest five-year swings in Net Cash Flow: plummeted 219.21% in 2018 and later skyrocketed 1301.71% in 2019.
  • Year by year, Net Cash Flow stood at -$806020.0 in 2017, then increased by 9.99% to -$725482.0 in 2018, then surged by 1301.71% to $8.7 million in 2019, then plummeted by 114.31% to -$1.2 million in 2020.
  • Business Quant data shows Net Cash Flow for MNPR at -$1.2 million in Q4 2020, $5.4 million in Q3 2020, and -$49070.0 in Q2 2020.